Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshio Ogihara

Showing results (21-30 of 337) with videos related to

Pageof 34
Sort By:
Experimental Physiology|March 22, 2005
Does gene therapy become pharmacotherapy?Ryuichi Morishita, Motokuni Aoki, Toshio Ogihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 18, 2006
[Diabetic complications and their features in the elderly]Tomomi Fujisawa, Hiroshi Ikegami, Toshio Ogihara
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 15, 2003
Therapeutic potential of oligonucleotide-based therapy in cardiovascular diseaseRyuichi Morishita, Yasufumi Kaneda, Toshio Ogihara
Current Drug Targets|October 28, 2003
Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their designNaruya Tomita, Toshio Ogihara, Ryuichi Morishita
Current Hypertension Reports|March 9, 2002
Vascular signaling pathways in the metabolic syndromeHiromi Rakugi, Kei Kamide, Toshio Ogihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 28, 2002
[Pharmacological effects of HMG-CoA reductase inhibitors]Naruya Tomita, Ryuichi Morishita, Toshio Ogihara
Clinical Calcium|January 7, 2006
[Recent multi-center clinical studies about calcium blockade and cardiovascular diseases]Kazuhiko Ishikawa, Hiromi Rakugi, Toshio Ogihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 8, 2006
[Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans]Kazunari Ozaki, Ryuichi Morishita, Toshio Ogihara
Current Opinion in Molecular Therapeutics|June 5, 2002
Potential therapeutic applications of decoy oligonucleotidesNaruya Tomita, Ryuichi Morishita, Tetsuya Tomita, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 10, 2009
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT studyToshio Ogihara, Takao Saruta, Kazuyuki Shimada, et al.
Pageof 34

Showing results (21-30 of 337) with videos related to

Sort By:
Pageof 34
Experimental Physiology|March 22, 2005
Does gene therapy become pharmacotherapy?Ryuichi Morishita, Motokuni Aoki, Toshio Ogihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 18, 2006
[Diabetic complications and their features in the elderly]Tomomi Fujisawa, Hiroshi Ikegami, Toshio Ogihara
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 15, 2003
Therapeutic potential of oligonucleotide-based therapy in cardiovascular diseaseRyuichi Morishita, Yasufumi Kaneda, Toshio Ogihara
Current Drug Targets|October 28, 2003
Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their designNaruya Tomita, Toshio Ogihara, Ryuichi Morishita
Current Hypertension Reports|March 9, 2002
Vascular signaling pathways in the metabolic syndromeHiromi Rakugi, Kei Kamide, Toshio Ogihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 28, 2002
[Pharmacological effects of HMG-CoA reductase inhibitors]Naruya Tomita, Ryuichi Morishita, Toshio Ogihara
Clinical Calcium|January 7, 2006
[Recent multi-center clinical studies about calcium blockade and cardiovascular diseases]Kazuhiko Ishikawa, Hiromi Rakugi, Toshio Ogihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 8, 2006
[Overview on diagnosis, treatment and therapeutic angiogenesis for arteriosclerosis obliterans]Kazunari Ozaki, Ryuichi Morishita, Toshio Ogihara
Current Opinion in Molecular Therapeutics|June 5, 2002
Potential therapeutic applications of decoy oligonucleotidesNaruya Tomita, Ryuichi Morishita, Tetsuya Tomita, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 10, 2009
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT studyToshio Ogihara, Takao Saruta, Kazuyuki Shimada, et al.
Pageof 34